Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dopamine - BrePco Biopharma

Drug Profile

Dopamine - BrePco Biopharma

Alternative Names: BCO-001; Neoatricon

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BrePco Biopharma
  • Developer Aspire Health Science; BrePco Biopharma
  • Class Antihypotensives; Behavioural disorder therapies; Cardiotonics; Catecholamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Dopamine D1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypotension
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypotension

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for preclinical development in Hypotension(In neonates) in United Kingdom (IV, Infusion)
  • 04 Jan 2023 BrePco Biopharma expects approval from European Medicines Agency for Hypotension in mid-to late-2023 (BrePco Biopharma website; January 2023)
  • 01 Oct 2019 BrePco Biopharma terminates the phase III HIP trial in Hypotension (In Neonates) in Belgium, Canada, Czech Republic, Ireland and United Kingdom due to poor recruitment (NCT01482559)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top